EMEA Cancer Biological Therapy Market to Exceed USD 29 Bn by 2023, Expects MRFR in Its In-Depth Report Now Available at MarketPublishers.com
13 Jul 2017 • by Natalie Aster
LONDON – Cancer ranks the leading and the 2nd largest cause of death across the globe. Nowadays, a wide range of approved biological therapies are adopted and used by different cancer specialists from pole to pole. Furthermore, there are many therapies under R&D. Biological therapy of cancer is conducted with the assistance of various living organisms, parts of living organisms or laboratory prepared version of such content.
The Europe, Middle East and Africa (EMEA) market for cancer biological therapy is set to go beyond USD 29.77 billion, posting healthy growth at a 5% CAGR through 2023.
Amid all market segments, targeted therapy is the fastest growing one in EMEA, it is predicted to increase at a 5.7% CAGR between 2017 and 2023.
As for end-users, the EMEA cancer biological therapy market is dominated by the hospitals and clinics segments, which holds the largest share of the total market.
Regionally, Europe is an absolute leader in the EMEA regional market for biological therapy. Europe’s market for monoclonal antibodies cancer biological therapy is anticipated to exceed USD 6.8 billion by the year 2021. Meanwhile, the cancer biological therapy market in Middle East and Africa is likely to see steady growth through 2023.
The comprehensive research report created by Market Research Future (MRFR), titled “Europe, Middle East and Africa Cancer Biological Therapy Market – Estimation & Forecast, 2013-2023”, offers a deep insight into the current situation in the regional market and outlines future possible trends in the EMEA cancer biological therapy market. The report analyses the main market growth driving and limiting factors, highlights the major market growth challenges, restraints, hinders and opportunities. the report reviews the historical and present performance of the total market and its segments, explores the situation across the key country markets in the region, discloses reliable statistics. Additionally, the report comprises an overview of the market competitive landscape and detailed profiles of the key players in the marketplace with data on their product offerings and business performance, financial details, SWOT analyses and data on the recent developments. Future forecasts for the EMEA cancer biological therapy market development through 2023 is also at hand here.
Other topical research reports elaborated by Market Research Future (MRFR) are available in its catalogue at MarketPublishers.com.